Filing Flows › Treace Medical Concepts (TMCI) › Q3 2026 › vs Q3 2025
Treace Medical Concepts (TMCI) Q3 2026 vs Q3 2025 (year over year)
Treace Medical Concepts's revenue fell $2.0M (-4%) from $50.2M in Q3 2025 to $48.3M in Q3 2026.
Treace Medical Concepts, Q3 2026: revenue $48.3M (-4% year over year), operating margin -23.9%, net loss $12.6M, operating cash flow −$3.3M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $48.3M | $50.2M | −$2.0M | -4% |
| Net loss | $12.6M | $16.3M | −$3.7M | -23% |
| Costs & expenses | $60.8M | $66.5M | −$5.7M | -9% |
| Operating costs | $59.8M | $65.9M | −$6.1M | -9% |
| Interest & other, net | $1.0M | $612K | $422K | +69% |
| Cost of revenue | $9.9M | $10.5M | −$605K | -6% |
| Research & development | $4.5M | $4.7M | −$188K | -4% |
| Sales & marketing | $29.7M | $34.4M | −$4.7M | -14% |
| General & admin | $15.7M | $16.3M | −$599K | -4% |
| Operating cash sources | $12.6M | $16.3M | −$3.7M | -23% |
| Depreciation & amortization | $2.0M | $2.8M | −$746K | -27% |
| Share-based compensation | $6.9M | $8.0M | −$1.1M | -13% |
| Working capital & other | $348K | −$3.6M | $3.9M | — |
| Cash used in operations | $3.3M | $9.1M | −$5.8M | -64% |
| Net loss absorbed | $12.6M | $16.3M | −$3.7M | -23% |
Questions
How much did Treace Medical Concepts's revenue grow year over year in Q3 2026?
Treace Medical Concepts's revenue fell $2.0M (-4%) from $50.2M in Q3 2025 to $48.3M in Q3 2026.